2023 World Conference on Lung Cancer (Posters)-EP12.01. Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib

EP12.01. Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the prevalence and details of osteoblastic bone reaction (OBR) in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and treated with osimertinib. OBR refers to an increase in bone density or the appearance of new sclerotic bone lesions after anticancer treatment. The study retrospectively reviewed patients diagnosed with EGFR-mutant NSCLC with bone metastasis who received osimertinib as first-line treatment.<br /><br />The study found that out of the 45 patients included in the analysis, 37 (82%) developed OBR, while 8 (18%) did not. The majority of patients were females with adenocarcinoma histology and the most common type of EGFR mutation was exon 19 deletion. The most common sites of bone metastasis were the vertebra, ribs, pelvis, and others. OBR was observed in various radiological types of bone metastasis, including sclerotic, lytic, and mixed.<br /><br />The study also evaluated the association between OBR and clinical outcomes. Although there was no significant difference in SRE-free survival (SRE-FS) between the OBR and non-OBR groups in the multivariate analysis, the median SRE-FS was longer in the OBR group compared to the non-OBR group (26 months vs. 12 months).<br /><br />The study highlights the relatively high prevalence of OBR in patients treated with osimertinib compared to previous studies with different treatment regimens. The authors suggest that OBR may not only be an increase in bone density on CT scans but also an increase in practical bone intensity, which should be taken into consideration to avoid misinterpreting OBR as disease progression.<br /><br />In conclusion, this study provides insights into the prevalence, details, and clinical outcomes associated with OBR in NSCLC patients with EGFR mutation treated with osimertinib. Understanding the characteristics of OBR can contribute to improved management and interpretation of bone metastasis in these patients.

Asset Subtitle

Kensuke Kanaoka

Meta Tag

Speaker Kensuke Kanaoka

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

osteoblastic bone reaction

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR mutation

osimertinib

bone metastasis

sclerotic bone lesions

clinical outcomes

disease progression